[1]
|
Iyer Krishna, S. and Dayal, S. (2020) Modulators of Platelet Function in Aging. Platelets, 31, 474-482.
https://doi.org/10.1080/09537104.2019.1665641
|
[2]
|
Veltkamp, R., Rizos, T. and Horstmann, S. (2013) Intracerebral Bleeding in Patients on Antithrombotic Agents. Seminars in Thrombosis and Hemostasis, 39, 963-971. https://doi.org/10.1055/s-0033-1357506
|
[3]
|
Potpara, T.S., Ferro, C.J. and Lip, G.Y.H. (2018) Use of Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction. Nature Reviews Nephrology, 14, 337-351. https://doi.org/10.1038/nrneph.2018.19
|
[4]
|
Eikelboom, J.W., Connolly, S.J., Gao, P., Paolasso, E., De Caterina, R., Husted, S., O’Donnell, M., Yusuf, S. and Hart, R.G. (2012) Stroke Risk and Efficacy of Apixaban in Atrial Fibrillation Patients with Moderate Chronic Kidney Disease. Journal of Stroke and Cerebrovascular Diseases, 21, 429-435.
https://doi.org/10.1016/j.jstrokecerebrovasdis.2012.05.007
|
[5]
|
Kubitza, D., Becka, M., Wensing, G., Voith, B. and Zuehlsdorf, M. (2005) Safety, Pharmacodynamics, and Pharmacokinetics of BAY 59-7939—An Oral, Direct Factor Xa Inhibitor-After Multiple Dosing in Healthy Male Subjects. European Journal of Clinical Pharmacology, 61, 873-880. https://doi.org/10.1007/s00228-005-0043-5
|
[6]
|
Stöllberger, C. and Finsterer, J. (2021) Update on Drug Interactions with Non-Vitamin-K-Antagonist Oral Anticoagulants for Stroke Prevention in Elderly Patients. Expert Review of Clinical Pharmacology, 14, 569-581.
https://doi.org/10.1080/17512433.2021.1908124
|
[7]
|
da, S.R.M. (2014) Novel Oral Anticoagulants in Non-Valvular Atrial Fibrillation. Cardiovascular & Hematological Agents in Medicinal Chemistry, 12, 3-8. https://doi.org/10.2174/187152571201141201091848
|
[8]
|
McBride, B.F. (2005) A Preliminary Assessment of the Critical Differences between Novel Oral Anticoagulants Currently in Development. The Journal of Clinical Pharmacology, 45, 1004-1007.
https://doi.org/10.1177/0091270005278084
|
[9]
|
Lin, L.S., Zhao, L.Y., Gao, N., et al. (2020) From Multi-Target Anticoagulants to DOACs, and Intrinsic Coagulation Factor Inhibitors. Blood Reviews, 39, Article ID: 100615. https://doi.org/10.1016/j.blre.2019.100615
|
[10]
|
Kuijpers, M.J., van der Meijden, P.E., Feijge, M.A., Mattheij, N.J., May, F., Govers-Riemslag, J., et al. (2014) Factor XII Regulates the Pathological Process of Thrombus Formation Onruptured Plaques. Arteriosclerosis, Thrombosis, and Vascular Biology, 34, 1674-1680. https://doi.org/10.1161/ATVBAHA.114.303315
|
[11]
|
Kakkos, S.K., Kirkilesis, G.I. and Tsolakis, I.A. (2014) Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of VTE: A Systematic Review and Meta-Analysis of Phase III Trials. European Journal of Vascular and Endovascular Surgery, 48, 565-575.
https://doi.org/10.1016/j.ejvs.2014.05.001
|
[12]
|
Pollack, C.V., Reilly, P.A., Eikelboom, J., et al. (2015) Idarucizumab for Dabigatran Reversal. The New England Journal of Medicine, 373, 511-520. https://doi.org/10.1056/NEJMoa1502000
|
[13]
|
Patti, G., Cavallari, I., Hanon, O., et al. (2018) The Safety and Efficacy of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation in the Elderly. International Journal of Cardiology, 265, 118-124.
https://doi.org/10.1016/j.ijcard.2018.02.066
|
[14]
|
Malik, A.H., Yandrapalli, S., Aronow, W.S., et al. (2019) Meta-Analysis of Direct-Acting Oral Anticoagulants Compared with Warfarin in Patients >75 Years of Age. American Journal of Cardiology, 123, 2051-2057.
https://doi.org/10.1016/j.amjcard.2019.02.060
|
[15]
|
Zathar, Z., Karunatilleke, A., Fawzy, A.M., et al. (2019) Atrial Fibrillation in Older People: Concepts and Controversies. Frontiers in Medicine (Lausanne), 6, 175. https://doi.org/10.3389/fmed.2019.00175
|
[16]
|
He, W., Zhang, H., Zhu, W. and Xue, Z. (2019) Effect of Anticoagulation Therapy in Older Patients with Chronic Kidney Disease and Atrial Fibrillation: A Meta-Analysis. Medicine (Baltimore), 98, e17628.
https://doi.org/10.1097/MD.0000000000017628
|
[17]
|
Diener, H.C., Hart, R.G., Koudstaal, P.J., Lane, D.A. and Lip, G.Y.H. (2019) Atrial Fibrillation and Cognitive Function: JACC Review Topic of the Week. Journal of the American College of Cardiology, 73, 612-619.
https://doi.org/10.1016/j.jacc.2018.10.077
|
[18]
|
Chai-Adisaksopha, C., Hillis, C., Monreal, M., Witt, D.M. and Crowther, M. (2015) Thromboembolic Events, Recurrent Bleeding and Mortality after Resuming Anticoagulant Following Gastrointestinal Bleeding. A Meta-Analysis. Thrombosis and Haemostasis, 114, 819-825. https://doi.org/10.1160/TH15-01-0063
|
[19]
|
Diener, H.C., Aisenberg, J., Ansell, J., Atar, D., Breithardt, G., Eikelboom, J., Ezekowitz, M.D., Granger, C.B., Halperin, J.L., Hohnloser, S.H., Hylek, E.M., Kirchhof, P., Lane, D.A., Verheugt, F.W.A., Veltkamp, R. and Lip, G.Y.H. (2017) Choosing a Particular Oral Anticoagulant and Dose for Stroke Prevention in Individual Patients with Non-Valvular Atrial Fibrillation: Part 2. European Heart Journal, 38, 860-868.
https://doi.org/10.1093/eurheartj/ehw069
|
[20]
|
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A.J. and Kirchhof, P. (2015) Updated European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Anticoagulants Inpatients with Non-Valvular Atrial Fibrillation. Europace, 17, 1467-1507.
https://doi.org/10.1093/europace/euv309
|
[21]
|
Bando, S., Nishikado, A., Hiura, N., et al. (2018) Efficacy and Safety of Rivaroxaban in Extreme Elderly Patients with Atrial Fibrillation: Analysis of the Shikoku Rivaroxaban Registry Trial (SRRT). Journal of Cardiology, 71, 197-201.
https://doi.org/10.1016/j.jjcc.2017.08.005
|
[22]
|
Zhang, X., Cai, Q.Y., Wang, X.H., Liao, K., Hu, C.C. and Chen, H. (2021) Current Use of Rivaroxaban in Elderly Patients with Venous Thromboembolism (VTE). Journal of Thrombosis and Thrombolysis, 52, 863-871.
https://doi.org/10.1007/s11239-021-02415-5
|
[23]
|
The EINSTEIN-PE Investigators (2012) Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. The New England Journal of Medicine, 366, 1287-1297. https://doi.org/10.1056/NEJMoa1113572
|
[24]
|
Giustozzi, M., Franco, L., Vedovati, M.C., et al. (2019) Safety of Direct Oral Anticoagulants versus Traditional Anticoagulants in Venous Thromboembolism. Journal of Thrombosis and Thrombolysis, 48, 439-453.
https://doi.org/10.1007/s11239-019-01878-x
|
[25]
|
Brenner, B., Arya, R., Beyer-Westendorf, J., et al. (2019) Evaluation of Unmet Clinical Needs in Prophylaxis and Treatment of Venous Thromboembolism in At-Risk Patient Groups: Pregnancy, Elderly and Obese Patients. Thrombosis Journal, 17, 24. https://doi.org/10.1186/s12959-019-0214-8
|
[26]
|
Hu, B.S., Jiang, L.X., Tang, H.X., Hu, M.Z., Yu, J. and Dai, Z.P. (2021) Rivaroxaban versus Aspirin in Prevention of Venous Thromboembolism Following Total Joint Arthroplasty or Hip Fracture Surgery: A Meta-Analysis. Journal of Orthopaedic Surgery and Research, 16, Article No. 135. https://doi.org/10.1186/s13018-021-02274-z
|
[27]
|
Zannad, F., Stough, W.G., Regnault, V., et al. (2013) Isthrombosis a Contributor to Heart Failure Pathophysiology? Possible Mechanisms, Therapeutic Opportunities, and Clinical Investigation Challenges. International Journal of Cardiology, 167, 1772-1782. https://doi.org/10.1016/j.ijcard.2012.12.018
|
[28]
|
Eikelboom, J.W., Connolly, S.J., Bosch, J., et al. (2017) Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. The New England Journal of Medicine, 377, 1319-1330. https://doi.org/10.1056/NEJMoa1709118
|
[29]
|
Giugliano, R.P., Ruff, C.T., Braunwald, E., et al. (2013) Edoxaban versus Warfarin in Patients with Atrial Fibrillation. The New England Journal of Medicine, 369, 2093-2104. https://doi.org/10.1056/NEJMoa1310907
|
[30]
|
Perera Kanjana, S., Ng Kelvin, K.H., Nayar, S., et al. (2020) Association between Low-Dose Rivaroxaban with or without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the Compass Trial. JAMA Neurology, 77, 43-48. https://doi.org/10.1001/jamaneurol.2019.2984
|
[31]
|
Yiu, A. and Bajorek, B. (2019) Patient-Focused Interventions to Support Vulnerable People Using Oral Anticoagulants: A Narrative Review. Therapeutic Advances in Drug Safety, 10. https://doi.org/10.1177/2042098619847423
|
[32]
|
Chan, N.C. and Eikelboom, J.W. (2019) How I Manage Anticoagulant Therapy in Older Individuals with Atrial Fibrillation or Venous Thromboembolism. Blood, 133, 2269-2278. https://doi.org/10.1182/blood-2019-01-846048
|